The remaining four teams will receive a small amount of seed funding – around £50,000 each – to help them win the £30 million funding award.
News
Cervical screening numbers hit ‘new low’
The “worrying trend” shows that less than three-quarters of women invited for cervical screening take it up.
QiC Dermatology now open for entries
QiC Programmes are run by PMGroup and were first launched in 2011 to bring the NHS, industry and patient groups closer together.
‘Make use of community pharmacists’, NICE urges
NICE is urging patients to ask their pharmacist advice about smoking, alcohol or maintaining a healthy weight.
Sunosi approved in Europe for EDS in narcolepsy, sleep apnoea
The European Commission has accepted the drug to improve wakefulness and reduce excessive daytime sleepiness in the disorders.
PhoreMost enlists Otsuka in multi-project drug discovery collab
The partnership will have an initial focus on gene therapy applications of identified targets.
NICE rejects Janssen’s Stelara on cost efficiency grounds
The annual treatment costs are £14,482 in the induction year, and £9,304 per year for maintenance treatment.
Darzalex EU nod marks first newly diagnosed MM treatment in six years
The approval was based on results from part one of the Phase III CASSIOPEIA study.
Fight for Sight to fund macular degeneration research
As it stands, damage to the macula can’t be reversed, making it the most common cause of permanent and severe sight loss in the UK.
EU clears Roche’s Polivy for certain lymphomas
The drug has been approved in combination with bendamustine and MabThera.
New scan could see active breast tumour regions in ‘real-time’
Breast cancer is the most common type of cancer in the UK, with around 55,000 new cases each year.
EMA licenses Mayzent for MS
Novartis also expects NICE and SMC decisions in the first half of 2020.
‘Weak antibiotic pipeline’ poses threat to AMR fight
Of the 60 products in development, very few seem to show benefit over existing treatments.
HIV transmissions fall by 71%
The UK is “well on its way towards our ambition of zero HIV transmissions by 2030.”
Heart failure market could surpass ‘$22bn by 2028’
Due to the aging global population, recent years have seen an increased prevalence of chronic HF.
